Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Citius Oncology

CTOR

0.86008.56% ( +0.0678 )

Closed: Sep 4, 16:00:01 (EDT)

OverviewOverview OptionsOptions NewsNews PostsPosts FinancialsFinancials ForecastForecast ValuationValuation ShareholdersShareholders ProfileProfile

LongbridgeAI

Citius Oncology (CTOR)

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan...

Open: 0.7666
High: 0.8816
Low: 0.7501
Prev. Close: 0.7922
Volume: 54.79K
Turnover: 44.00K
Avg Price: 0.8031
Bid/Ask Ratio: --
Amplitude: 16.60%
52wk High: 2.2500
Volume Ratio: 0.35
Turnover Ratio: 0.18%

52wk Low: 0.4912
Float Mkt Cap: 26.64M
Market Cap^USD: 90.95M
P/E^TTM: Loss
P/E^Dynamic: Loss
P/E^Static: --
EPS^TTM: -0.436
EPS^Dynamic: -0.338
EPS^Static: --
BVPS: 0.38
P/B: 2.25
Circulating Supply: 30.98M
Dividend Yield^TTM: --
Dividend^TTM: --
Shares: 105.76M
Min lot size: 1
Currency: USD

Citius Oncology Analyst Rating

Forecast & Rating

Aug 7, 2026

Price forecast

$4.00365.12%

Forecast & RatingBuy

1analysts

Strong buy0.00%
Buy100.00%
Hold0.00%
Sell0.00%
Strong sell0.00%

Strong buy: 0
Buy: 1
Hold: 0
Sell: 0
Strong sell: 0

News

Market Beat · Sep 2 at 07:05 AM
Bank of America Corp DE Acquires 3,834,946 Shares of Citius Oncology, Inc. $CTOR
Unusual Whales · Aug 17 at 03:34 PM
Groundbreaking Research by CTOR Explores the Connection Between Bite, Facial Growth and Breathing
Earnings Watch · Aug 14 at 09:14 PM
Citius Oncology | 8-K: FY2026 Q3 Revenue: USD 1.494 M
StockTitan · Aug 14 at 12:30 PM
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update | CTOR Stock News
PUBT · Aug 12 at 12:06 PM
Citius Oncology appoints Jonathan Peri as independent director, expands board to nine members